Elix Provides AI Drug Discovery Platform “Elix Discovery™” to Eisai
Elix, Inc. (CEO: Shinya Yuki / Headquarters: Tokyo; hereinafter “Elix”) is pleased to announce that its AI drug discovery platform, Elix Discovery (https://www.elix-inc.com/platform/), has been adopted by Eisai Co., Ltd. (Headquarters: Tokyo; hereinafter “Eisai”). Traditional drug discovery involves identifying promising compounds from vast numbers of candidates, which leads to long development timelines, high costs, and…
